{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'In the preclinical studies, activation of -adrenergic receptors by stress hormones has been found to', 'play significant role in tumour progression. The AC-cAMP-PKA pathway enables phosphorylation of', 'CREB that induces the transcription of genes encoding numerous factors responsible for angiogenesis', '(VEGF), tissue invasion (matrix metalloproteinases [MMPs] 2/9), and inflammation (IL-6, IL-8). The', 'CAMP/PKA/phosphoinositide 3-kinase (PI3K)/Akt/mTOR/p70S6 kinase stimulates VEGF expression', 'dependent on HIF1a [21-24]. The PKA-independent pathway was reported to induce NFkB and', 'activator protein 1 (AP-1) that regulate the translation of VEGF, MMPs and interleukins [25]. The', 'stimulation of 2-adrenoceptors activates actin-related proto-oncogene tyrosine-protein kinase Src', 'and subsequently phosphorylation of focal adhesion kinase (FAK) that results in lower level of anoikis', '[26]. Furthermore, 2-adrenoceptor stimulation by adrenaline leads to PKA-dependent BCL2-', 'associated death protein (BAD) phosphorylation which results in resistance to chemotherapy-', 'induced apoptosis [27]. The activation of PKA-dependent pathway by NE results in Src and signal', 'transducer and activator of transcription-3 (STAT-3) stimulation that may drive the growth, invasion', 'and metastasis process in ovarian cancer [28, 29]. On the other hand, a metastatic switch may be', 'triggered by the tumour-infiltrating macrophages that produce various pro-metastatic factors after', 'stress hormones release [30]. The -adrenergic signaling may also inhibit p53-mediated DNA repair', '[31], suppress cytotoxic T lymphocyte and natural killer (NK) cell responses [32], inhibit expression of', 'interferons [33], upregulate the human epidermal growth factor receptor 2 (HER2) signaling pathway', '[34] and induce the snail family transcriptional repressor 2 (SNAI2) which regulates the epithelial-', 'mesenchymal transition (EMT) [35].', 'Theoretically, the \u00df-adrenergic tumour growth might be driven via circulating catecholamines or via', 'NE local release from SNS nerve fibers. Recent studies, however, suggest that the second option is', 'most possible. In ovarian cancer tissues E is not detectable and concomitantly NE levels are higher', 'than those in circulating blood. What is more, intratumour NE levels correlate with patient', 'psychosocial risk factors and with tumor gene expression profiles, whereas NE and E blood levels do', 'not [36, 37]. Human breast and ovarian cancer tissues are extensively innervated by peri-vascular', 'fibers that may supply tumour and stromal cells with NE [30, 38]. It was also found that social stress', 'enhances sympathetic innervation of primate lymph nodes [39] and similar phenomenon in tumour', 'tissues cannot be excluded.', '1.1.4 The Place of Sunitinib in Treatment of Metastatic RCC', 'Surgical resection remains the only known effective treatment for localized renal cell carcinoma, but', 'it also is used for palliation in metastatic disease. Clinical studies showed that nephrectomy increases', 'effectiveness of further systemic therapies [40, 41]. Moreover, if the metastases are singular and', 'resectable, metastasectomy should be also performed. Resection of single metastases from lung,', 'brain or liver can provide a long time without starting a systemic treatment [42, 43].', 'For decades, treatment with classic chemotherapy was unsuccessful in patients with metastatic', 'disease. Interleukin-2 (II-2) and Interferon alpha (IFN-a) introduced in 1990s were the first drugs that', 'were able to evoke dramatic and durable tumor regression, however in small percentage of patients', 'with significant toxic side effects [44]. Sequencing of human VHL (von Hippel-Lindau) gene and the', 'discovery that its abnormalities are found in majority of clear-cell RCC cases were a mile-step in', 'development of active agents. Currently, they include VEGFR-targeted tyrosine kinase inhibitors', '(sorafenib, sunitinib, pazopanib, axitinib, lenvatinib and cabozantinib), VEGF antibody (bevacizumab),', 'Page 15 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'mTOR pathway inhibitors (temsirolimus and everolimus) and programmed death-1 (PD-1) antibody', '(nivolumab) [45]. All these agents demonstrated clinical benefit in many investigational studies and', 'have been approved by the US Food and Drug Administration (FDA) and the European Medicines', 'Agency (EMA).', 'Sunitinib is an orally administrated drug that was approved by FDA in 2005. It is an inhibitor of', 'platelet-derived growth factor receptor (PDGFR) -a, -\u00df, vascular endothelial growth factor receptor', '(VEGFR) -1, -2, -3, KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), FLT-3 (fms-', 'related tyrosine kinase 3), CSF-1R (colony stimulating factor 1 receptor) and rearranged during', 'transfection (RET) proto-oncogene. In a large phase III registration study (NCT00098657) sunitinib', 'was superior in efficacy when compared to IFN-a in the control arm. There were 750 previously', 'untreated patients with metastatic disease enrolled into the trial, with randomization ratio 1:1 in', 'both arms. Patients in investigational arm received sunitinib at a dose of 50 mg daily for four weeks,', 'then two weeks without medication (a six-week cycle). In control arm IFN-a was given as a', 'subcutaneous injection three times per week on nonconsecutive days at 3 million units (MU) per', 'dose during the first week, 6 MU per dose the second week, and 9 MU per dose thereafter. A dose', 'reduction was allowed due to severe or uncontrolled adverse effects (to 37.5 mg and then to 25 mg', 'daily for sunitinib, and to 6 MU and then to 3 MU three times per week for IFN-a). Median', 'progression-free survival (PFS) was 11.0 months for sunitinib vs 5.0 months for IFN-a (Hazard Ratio', '[HR]=0.42, 95% Confidence Interval [CI]: 0.32-0.54, p<0.001). Median overall survival (OS) was 24.6', 'vs. 21.8 (HR=0.821, 95% CI: 0.673-1.001, p=0.051) and objective response rate (ORR) was 31% (95%', 'CI: 26 to 36) vs. 6% (95% CI: 4% to 9%) for sunitinib and IFN-a, respectively. All-grade adverse events', 'occurred more frequently in the sunitinib group than in the IFN-a group. Patients in the sunitinib', 'group, as compared with those in the IFN-a group, had higher rates of grade 3 diarrhea (5% vs. no', 'cases), vomiting (4% vs. 1%), hypertension (8% vs. 1%), and the hand-foot syndrome (5% vs. no', 'cases, p<0.05 for all comparisons). Treatment-related grade 3 or 4 fatigue was significantly higher', 'among patients in the IFN-a group than in the sunitinib group (12% vs. 7%, p<0.05). Grade 3 or 4', 'leukopenia, neutropenia, and thrombocytopenia occurred more often in the sunitinib group than in', 'the IFN-a group (p<0.05 for all comparisons) [46]. In a retrospective, population-based analysis,', 'efficacy of sunitinib was similar as in the registration study. Based on data of 6159 sunitinib-treated', 'patients, median os was 22.3 months (95% CI: 21.4-23.2), whereas median PFS was 8.4 months (95%', 'CI 8.2-8.7). Response to sunitinib therapy was assessed in 5561 patients of whom 1687 (30%)', 'achieved complete response (CR) or partial response (PR) [47]. Recent retrospective analysis of', 'Bracarda et al. showed improved safety profile of patients who moved to a modified 2/1 schedule of', 'sunitinib compared with that observed during the initial 4/2 schedule, without sacrifice the efficacy', '[48]. In a randomized phase II study of Lee et al., sunitinib administered with a 2/1 schedule was', 'associated with less toxicity and higher 6-month failure-free survival than a 4/2 schedule, without', 'compromising the efficacy in terms of ORR and time-to-progression [49].', '1.2 Propranolol', '1.2.1 Pharmacology', 'Propranolol (1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol), firstly developed in the 1960s,', 'is a non-cardioselective sympatholytic -adrenergic blocker with a similar binding affinity for \u00df1- and', 'Page 16 of 60']\n\n###\n\n", "completion": "END"}